Track the Definium Therapeutics, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €5.5bn. The latest transaction was reported on 4 September 2026 (Attribution). Among the most active insiders: Barrow Robert. All data is free.
37
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€1m
9 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Definium Therapeutics, Inc. Strong Buy (bullish), based on 17 analysts. Average price target: US$67.47.
36Σ signal
Buys n/a€1m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Definium Therapeutics, Inc. es una empresa centrada en el desarrollo de terapias innovadoras para el tratamiento de enfermedades graves. Cotiza en el mercado XNAS.